title: [A Case of HER2-Positive Breast Cancer Treated with Nipple-Sparing Mastectomywith Immediate Reconstruction Using a Tissue Expander after Nab-Paclitaxel Combined with Chemotherapy].
abstract: A 59-year-old woman presented to our hospital with a mass in her left breast. Mammography and ultrasound showed a 9 ×11×12mm mass in her left breast, and left axillary lymph adenopathy. Core needle biopsy and pathological examination confirmed the diagnosis of ER-negative, PgR-negative, HER2-positive invasive ductal carcinoma with axillary lymph metastasis. Dynamic computed tomography(CT)and bone scintigraphy showed no metastasis. A diagnosis ofbreast cancer with stage II A(T1N1M0)was made, and we started neoadjuvant chemotherapy. After 4 cycles of chemotherapy with 5-fluorouracil/ epirubicin/cyclophosphamide in 3-weekly cycles, we administered combination chemotherapy ofnab -paclitaxel and trastuzumab in 3-weekly cycles. After 7 months, the tumor disappeared and the axillary lymph node got significantly smaller. We performed nipple-sparing mastectomy/axillary lymph nodes dissection/tissue-expander placement. The pathological examination ofthe resected tumor confirmed a pathological complete response(pCR). The patient was treated with implant reconstruction and adjuvant therapy. One year has passed after the surgery, and no significant problem has been observed.
authors.affiliation: Dept. of Surgery, Fuchu Hospital.
authors.forename: Ayami
authors.initials: A
authors.lastname: Nonomura
authors.forename: Naoki
authors.initials: N
authors.lastname: Aomatsu
authors.forename: Seika
authors.initials: S
authors.lastname: Tei
authors.forename: Goichi
authors.initials: G
authors.lastname: Haraoka
authors.forename: Gen
authors.initials: G
authors.lastname: Tsujio
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Yamakoshi
authors.forename: En
authors.initials: E
authors.lastname: Wang
authors.forename: Daisuke
authors.initials: D
authors.lastname: Nagashima
authors.forename: Toshiki
authors.initials: T
authors.lastname: Hirakawa
authors.forename: Takehiko
authors.initials: T
authors.lastname: Iwauchi
authors.forename: Takafumi
authors.initials: T
authors.lastname: Nishii
authors.forename: Junya
authors.initials: J
authors.lastname: Morimoto
authors.forename: Kazunori
authors.initials: K
authors.lastname: Nakazawa
authors.forename: Yasutake
authors.initials: Y
authors.lastname: Uchima
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Takeuchi
mesh_terms: D000418:Albumins / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D005260:Female; D006801:Humans; D016462:Mammaplasty; D008408:Mastectomy; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009558:Nipples / Q000000981:diagnostic imaging / Q000473:pathology / Q000601:surgery*; D017239:Paclitaxel / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D000068878:Trastuzumab / Q000008:administration & dosage
chemical_list: D000418:Albumins; D017239:Paclitaxel; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C520255:130-nm albumin-bound paclitaxel; C508053:ERBB2 protein, human